Zobrazeno 1 - 8
of 8
pro vyhledávání: '"S. A. Krasnyi"'
Autor:
S. A. Krasnyi
Publikováno v:
Onkourologiâ, Vol 3, Iss 2, Pp 34-41 (2020)
The results of a prospective randomized study of the efficacy of neoadjuvant chemoimmunotherapy with intravesical roncoleukin (interleukin- 2) versus the standard M-VAC chemotherapy regimen are analyzed. The study protocol included 60 patients. Addit
Autor:
S. A. Krasnyi
Publikováno v:
Onkourologiâ, Vol 3, Iss 1, Pp 69-75 (2020)
Publikováno v:
Onkourologiâ, Vol 3, Iss 3, Pp 35-41 (2020)
The data of 668 radical cystectomies were used to study the results of treatment in 151 (22,6%) patients with urinary bladder cancer (UBC) metastasizing to the regional lymph nodes and to evaluate the impact of lymphodissection extent on the detectio
Publikováno v:
Onkourologiâ, Vol 3, Iss 1, Pp 18-24 (2020)
Objective: The immediate and long-term results of nephron-sparing treatment for renal-cell carcinoma (RCC) were retrospectively assessed. The impact of several prognostic factors on treatment results was analyzed.Material and Methods: All cases of pa
Simultaneous Surgical Treatment of Patients with Renal Cell Carcinoma Concomitant with Heart Disease
Autor:
Yu. P. Ostrovsky, O. G. Sukonko, V. V. Zharkov, V. V. Andrushchuk, S. A. Krasnyi, S. L. Polyakov, T. G. Voitsun, D. I. Krachak, S. L. Solovyov
Publikováno v:
Onkourologiâ, Vol 2, Iss 1, Pp 10-12 (2020)
The authors analyze the immediate results of 8 simultaneous operations, 4 of these under conditions of artificial circulation, in patients with renal cell carcinoma concomitant with heart diseases. The immediate results were satisfactory, with good f
Publikováno v:
Onkourologiâ, Vol 12, Iss 1, Pp 58-62 (2016)
The prostate cancer (PC) screening program elaborated in the Republic of Belarus, which envisages the determination of prostate-specific antigen (PSA) levels once every two years among 50–65-year-old men and 6-point lateralized transrectal ultrasou
Publikováno v:
Onkourologiâ, Vol 11, Iss 3, Pp 62-70 (2015)
Проведено проспективное исследование по оценке прогностического значения мутационного статуса гена FGFR 3 у пациентов с раком мочевого п
Autor:
V. A. Alinovskaya, S. A. Krasnyi, A. I. Shmak, P. M. Bychkovski, T. L. Yurkshtovich, R. I. Kosterova, N. V. Golub, S. O. Solomevich, Yu. P. Istomin, M. Yu. Revtovich, Aleksandrova En, A. A. Kladiev, Z. B. Kvacheva, N. A. Petrovskaya
Publikováno v:
Pharmaceutical Chemistry Journal. 47:387-392
A new, long-acting form of prospidine was formulated by immobilization of the cytostatic agent on biodegradable dextran phosphate. Results from in vitro and in vivo studies of the antitumor activity of the long-acting prospidine formulation are prese